CTD Holdings, Inc. engages in the marketing and sale of cyclodextrins and related products. The company develops cyclodextrins-based applications in stabilization of flavors for food products; preparation of antifungal complexes for foods and toiletries; elimination of undesirable tastes and odors; stabilization of fragrances and dyes; reduction of foaming in foods; cosmetics and toiletries; and the improvement of quality, stability, and storability of foods. It also manufactures selected cyclodextrin complexes, as well as distributes cyclodextrins. CTD Holdings sell cyclodextrins, the molecules that bring oil and water together for applications in the areas of agriculture, analytical chemistry, biotechnology, cosmetics, diagnostics, electronics, foodstuffs, pharmaceuticals, and toxic waste treatment. In addition, the company provides consulting services for the commercialization of new products containing cyclodextrins, as well as sells own manufactured and licensed products containing cyclodextrins. It serves chemical supply houses, pharmaceutical companies, diagnostics companies, and food companies for research and development. The company was founded in 1990 and is based in High Springs, Florida.
As of March 3, 2014:
100,000,000 Shares Authorized
48,562,355 Issued and Outstanding
Source: March 3, 2014 10-K Filing
Insider Holdings - April 14, 2014
Sources: http://finance.yahoo.com/q/ir?s=CTDH+Insider+Roster and http://ir.stockpr.com/ctd-holdings/all-sec-filings/content/0001213900-14-001241/f10k2013_ctdholdingsinc.htm (Page 8)
33,187,647 (19,837,647 accounted for on SEC Form 4s - http://ir.stockpr.com/ctd-holdings/insiders/content/0000908662-14-000081/form4.html) - CE Rick Strattan
Public Float Estimated Float (April 14, 2014):
YouTube Videos - Great updates regularly released directly from CTD Holdings:
CTD Holdings April 2014 Update Video
April 22, 2014 - https://www.youtube.com/watch?v=j3Mj1TLoMlY
CTD Holdings March 2014 Update Video
March 14, 2014 - https://www.youtube.com/watch?v=drusCww4C4s
CTD Holdings Private Placement Update
February 21, 2014 - https://www.youtube.com/watch?v=tAztchHTUtc
CTD Holdings February 2014 Update Video
February 18, 2014 - https://www.youtube.com/watch?v=O6AjJSntJjg
CTD Holdings January 2104 Update Video
January 21, 2014 - https://www.youtube.com/watch?v=9azkQo03Zo8&list=UUAiuTaS4ib6_l3GlnDA9tDQ
CTD Holdings December 2013 Update Video
December 21, 2014 - https://www.youtube.com/watch?v=OM_EAIPKasE&list=UUAiuTaS4ib6_l3GlnDA9tDQ
Older Update Videos Available at:
Dr. Tate has been consistanly posted monthly update videos since 2010. Great way to see the history of this company.
CTD Holdings Fact Sheet
March 31, 2012 - http://content.stockpr.com/ctdholdings/media/747eeebeb6c96b81d74eee2eecff9687.pdf
WSR Equity Research Report
February 21, 2012 - http://www.wallstreetresources.net/pdf/fc/CTDH.pdf
CTD Holdings - Nanosonic Uses USDA Grant to Install Solar Energy System
October 19, 2011 - http://www.gainesville.com/article/20111019/ARTICLES/111019423?tc=ar
FDA Orphan Drug Status Designation - Trappsol
May 17, 2010 - http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=303910
Dateline Story on Addi & Cassi Hempel - Using Trappsol to Treat Niemann Pick Type C
January 5, 2010 - http://www.youtube.com/watch?feature=player_embedded&v=se1Pzqjh26o
Cyclodextrin As A Therapeutic "Drug" For HIV AIDS, Niemann Pick Type C and other Viruses
April 16th, 2009 - http://webofhope.com/2009/04/cyclodextrin-as-a-theraputic-drug-for-hiv-aids-niemann-pick-type-c-and-other-viruses/
Mentioned in a Wall Street Journal Article:
Cyclodextrin - Wikipedia:
CEO Rick Strattan - Personally thanked following FDA Approval:
Trappsol Google Search Results:
Cyclodextrin in the News:
What is a Cyclodextrin?
CDs are molecules that bring together oil and water and have potential applications anywhere oil and water must be used together. Successful applications have been made in the areas of agriculture, analytical chemistry, biotechnology, cosmetics, diagnostics, electronics, foodstuffs, pharmaceuticals and toxic waste treatment. Stabilization of food flavors and fragrances is the largest current worldwide market for CD applications. We and others have developed CD-based applications in stabilization of flavors for food products; elimination of undesirable tastes and odors; preparation of antifungal complexes for foods and toiletries; stabilization of fragrances and dyes; reduction of foaming in foods; cosmetics and toiletries; and the improvement of quality, stability and storability of foods.
CDs can improve the solubility and stability of a wide range of drugs. Many promising drug compounds are unusable or have serious side effects because they are either too unstable or too insoluble in water. Strategies for administering currently approved compounds involve injection of formulations requiring pH adjustment and/or the use of organic solvents. The result is frequently painful, irritating, or damaging to the patient. These side effects can be ameliorated by CDs. CDs also have many potential uses in drug delivery for topical applications to the eyes and skin.
We believe the application of CDs in both over the counter (OTC) and ethical ophthalmic products provides the quickest path to market for the introduction of preparations containing CDs for topical drug use.
CDs have been used in a variety of food products in Japan for over 25 years. In 1999, the economic impact of CDs on the Japanese economy was reported to be $2.6 billion. Within the last 10 years, many more European countries have approved the use of CDs in food products. In the United States, major starch companies are renewing their earlier interest in CDs as food additives. We believe the food additive industry world-wide will continue to increase its use of CDs.
Natural CDs have been confirmed to be generally recognized as safe ("GRAS") in most of the world, now including the U.S. Moreover, recent approvals of products containing CDs by the U.S. Food and Drug Administration ("FDA") suggest that regulatory approval for new products may be easier in the future. In 2001, Janssen Pharmaceutica, now a subsidiary of Johnson & Johnson, received FDA approval to market Sporanox®, an antifungal which contained hydroxypropyl BCD. In 2008, one of our clients used our product, Trappsol® HPB, in an FDA approved compassionate use clinical trial for the treatment of Niemann Pick Type C disease. We now sell this product under our Trappsol® product line as "Cyclo™." Our customer applied to the FDA to designate Trappsol® Cyclo™ as an orphan drug in the treatment of Niemann Pick Type C disease. Under the Orphan Drug Act, companies that develop a drug for a disorder affecting fewer than 200,000 people in the United States may seek designation as an orphan drug and, if such application is approved, they have the ability to sell it without competition for seven years, and may get clinical trial tax incentives. On May 17, 2010, the FDA designated Trappsol® Cyclo™ as an orphan drug for the treatment of Niemann Pick Type C (NPC) disease.
Applications of CDs in personal products and for industrial uses have appeared in many patents and patent applications. Procter & Gamble uses CDs in Bounce®, a popular fabric softener and Febreze®. Avon uses CDs in its dermal preparations using its Age Protective System (APS®). The prices of the natural CDs have decreased enough so that use of these materials will be more price competitive.
Name: C.E. Rick Strattan
Job Title: President and CEO
Phone: (386) 454-0887 ext. 22
Fax: (386) 454-8134
Name: George Fails
Job Title: Director of Field Operations
Phone: (386) 454-0887
Fax: (386) 454-8134
Name: Dr. Jeffrey Tate
Job Title: President/ CEO Nanosonic Products
Phone: (386) 418-8060
Board of Directors:
Latest News Releases:
April 16, 2014
CTD Holdings, Inc. Closes on Securities Purchase and Collaboration Agreement
March 11, 2014
CTD Holdins Reports Record Revenues for 2013
February 20, 2014
CTD Holdings, Inc. Closes on Private Placement